← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Kansas City Va Medical Center
Kansas City, MO
$0
Total funding
26
Grants
Funding over time
peak $0 · FY2009–25$1$1$1$0$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
VA$0 · 26
By mechanism
I01$0 · 22
I21$0 · 1
IK1$0 · 1
IK6$0 · 2
Investigators at Kansas City Va Medical Center
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
The Role of Cyr61 in Patho-Biology and Therapeutics of Pancreatic Cancer$0
I01 · FY2012 · VA
Persistent Attenuation of Cocaine-Reinforced Behavior$0
I01 · FY2012 · VA
New Strategy to Fight Selective Cholinergic Neuronal Loss in Alzheimer Disease$0
I01 · FY2014 · VA
Persistent Attenuation of Cocaine-Reinforced Behavior$0
I01 · FY2013 · VA
New Strategy to Fight Selective Cholinergic Neuronal Loss in Alzheimer Disease$0
I01 · FY2013 · VA
The Role of CCN5 in Progression of Breast Cancer$0
I01 · FY2014 · VA
Visuomotor rehabilitation training for manual task deficits from macular scotomas$0
I01 · FY2015 · VA
Inhibition of Cancer stem cell characterisitcs in Pancreatic Cancer$0
I01 · FY2015 · VA
Persistent Attenuation of Cocaine-Reinforced Behavior$0
I01 · FY2014 · VA
The Role of Cyr61 in Patho-Biology and Therapeutics of Pancreatic Cancer$0
I01 · FY2014 · VA
The Role of CCN5 in Progression of Breast Cancer$0
I01 · FY2013 · VA
The Role of CCN5 in Progression of Breast Cancer$0
I01 · FY2016 · VA
Persistent Attenuation of Cocaine-Reinforced Behavior$0
I01 · FY2015 · VA
New Strategy to Fight Selective Cholinergic Neuronal Loss in Alzheimer Disease$0
I01 · FY2015 · VA
Impacts of nicotinamide riboside on functional capacity and muscle physiology in older Veterans$0
I01 · FY2022 · VA
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure$0
I01 · FY2023 · VA
Obstructive Sleep Apnea-Triggered Cognitive Impairment and its Prevention$0
I01 · FY2017 · VA
Visuomotor rehabilitation training for manual task deficits from macular scotomas$0
I01 · FY2015 · VA
The Role of CCN5 in Progression of Breast Cancer$0
I01 · FY2015 · VA
CCN5 Therapy for Triple Negative Breast Cancer$0
I01 · FY2022 · VA